For research use only
| Cat No. | ABC-TC0148 |
| Product Type | Mouse Colon Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Mouse |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Rectum |
| Disease | Polyploid Cancer |
| Product Code | CMT93; CMT 93; C57 Mouse Tumor 93 |
Mouse rectum carcinoma. From a 19 month old male mouse (C57BL/1CRF) which had received an i.P. Injection of MAMA each week for 18 months.
CMT‑93 cell line is a mouse carcinoma derived from the rectum of a C57BL/1CRF mouse following prolonged chemical induction. These cells display an epithelial morphology and an adherent growth pattern, with the formation of acini and the presence of junctional complexes. They possess a hyperdiploid karyotype characterized by structural abnormalities and occasional polyploidy (~6–20%), including complex chromosomal rearrangements involving chromosomes 2, 5, 8, and X. In syngeneic C57BL/6 mice, CMT‑93 reliably forms liver metastases with characteristic gene expression changes supporting metastasis and angiogenesis. This line is microsatellite-stable and shows low intrinsic immunogenicity, making it suitable for immunocompetent preclinical models. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from mycoplasma, fungi, yeast, and bacteria.
| Product Code | CMT93; CMT 93; C57 Mouse Tumor 93 |
| Species | Mouse |
| Cat.No | ABC-TC0148 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Rectum |
| Disease | Polyploid Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Mouse Colon Cancer Cell Lines |
CMT‑93 is extensively applied in preclinical colorectal cancer research, especially for studying metastatic dissemination in immunocompetent mouse models via portal-vein injection, leading to liver colony formation. It is ideal for molecular studies of metastasis, including matrix metalloproteinases, Wnt signaling, and angiogenesis. With its moderate epithelial–mesenchymal traits and CD44 expression, it’s also valuable in exploring tumor cell plasticity, stemness, and immune evasion. The line supports evaluations of oncolytic viruses, radiotherapy, and immunotherapy regimens including checkpoint inhibitors, due to its low immunogenic profile and stable genetic background.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
